Delineation of the Relationships Between Proton Pump Inhibitor (PPI) Use and the Development of Osteoporosis and Osteoporosis Related Fractures

质子泵抑制剂 (PPI) 使用与骨质疏松症及骨质疏松症相关骨折发生之间关系的描述

• 批准号: 176317
• 负责人: Targownik Laura E
• 金额: $ 10.93万
• 依托单位: University of Manitoba
• 依托单位国家: 加拿大
• 项目类别: Salary Programs
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-09-01 至 2013-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=176317&lang=en
• 关键词: Fractrures; Gastroesophageal Reflux Disease (Gerd); Osteoporosis; Proton Pump Inhibitors

Proton pump inhibitors (PPIs) are among the most commonly prescribed medications in clinical practice. PPIs are the most effective medications for reducing the production of stomach acid, and as a result are very effective for the treatment and prevention

质子泵抑制剂（PPIs）是临床上最常用的处方药之一。PPIs是减少胃酸产生的最有效的药物，因此对治疗和预防非常有效